Stämm scales adherent cells by leveraging 3D printing and microfluidics

Monday, March 25, 2024 @ 10:00 am

The scaling of adherent cells presents numerous challenges. Particularly known for their difficulty in reproducing, requiring a highly precise controlled environment condition to guarantee expansion. Common issues include poor attachment to culture vessels, compromised viability due to oxygen and nutrient deficiencies, and inconsistent yields.

Stämm is fine-tunning its Human Tissue Platform, an automated microfluidic platform that enables efficient adherent cell culture amplification at required scale with precise automated control over the microenvironment, improving process efficiency and cost savings in biomass production compared to traditional methods of adherent cell scale-up.

It's composed of key features such as microfluidic channels, which enable optimized culture conditions and keep culture media volume constant throughout the expansion process, preventing variability that could harm consistent cell growth.

While in traditional control the results obtained were 30 thousand cells per cm2, Stämm’s bioreactor achieved 60 thousand cells per cm2.

As a result 400 thousand cells were inoculated in a 10ml 3D-printed bioreactor and an average of 5 million adherent cells were reached in 7 days.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

Nouscom appoints Neil Gallagher as independent advisor

Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the approval of multiple innovative medicines.
May 17, 2024

InSphero secures commercialization partnership with Genome Biologics

May 16, 2024

AC Immune and Takeda sign agreement for an Alzheimer immunotherapy

Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion AC Immune to host conference call an
May 13, 2024

Memo Therapeutics increases series C financing to CHF 45 million

Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation in kidney transplantation
May 7, 2024

Mabylon: Candidate nomination of an anti-allergen multispecific antibody for peanut allergy

In collaboration with Pfizer Ignite, Mabylon nominates its anti-allergen multispecific antibody product that is undergoing Investigative New Drug (IND)-enabling studies and subsequent clinical development for the treatment of peanut allergy.
May 10, 2024